This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Medical Practice  • Medical Ethics  • Dermatologic Disorders  • Statistics and Research Methods  • Psoriasis  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Kenneth A. Katz, MD, MSc, MSCE

Arch Dermatol. 2008;144(3):403-404.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In October 2005, clobetasol, 0.05%, spray (Clobex spray; Galderma Laboratories LP, Fort Worth, Texas), received US Food and Drug Administration (FDA) approval for treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area in patients 18 years or older.¹ A few months thereafter, I received a brochure inviting me to be an investigator in a study of Clobex spray that was called "CoBRA," an acronym for Community-Based Research Assessment.² "Join Us as an Investigator," the brochure read.^2(p1) It continued^2(p2):

While a number of therapeutic options [for psoriasis] exist, patient satisfaction with existing topical therapies tends to be low. Recently, several existing molecules have been reformulated with novel technology . . . [that] may enhance patient satisfaction. Therefore, it is important for physicians to be educated about the data supporting them and to gain valuable clinical experience with their use in order to make . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter